The Celltex Affair
By Carl Elliott,
Slate
| 02. 17. 2012
The stem-cell tourism industry is not exactly renowned for ethical probity, much less scientific rigor. Given its reputation for peddling untested remedies to desperate patients, not to mention its starring role in several sting operations on 60 Minutes, a few eyebrows went up when one of the nation's leading journals of medical ethics relocated to the offices of a commercial stem cell clinic in Sugar Land, Texas. In December, the editor of the American Journal of Bioethics, a man called Glenn McGee, took up a new job with Celltex Therapeutics as its president for ethics and strategic initiatives. He now works for a new business venture that is partnered with a shady South Korean company known for its commercial puppy-cloning ventures, and co-founded by the surgeon who made headlines last year by treating Rick Perry's back pain with unapproved adult stem cells. Some bioethicists are defending the move, suggesting that any potential conflicts of interest can be managed, but they have failed to appreciate the extent of McGee's questionable history with stem cell tourism—in particular, his...
Related Articles
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Aleks Krotoski, The Guardian | 09.28.2025
Imagine you’re the leader of one of the most powerful nations in the world. You have everything you could want at your disposal: power, influence, money. But, the problem is, your time at the top is fleeting. I’m not...
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...